Literature DB >> 20596752

The transglutaminase 2 gene is aberrantly hypermethylated in glioma.

Lisa M Dyer1, Kevin P Schooler, Lingbao Ai, Corinne Klop, Jingxin Qiu, Keith D Robertson, Kevin D Brown.   

Abstract

Transglutaminase 2 (TG2) is a ubiquitously expressed protein that catalyzes protein/protein crosslinking. Because extracellular TG2 crosslinks components of the extracellular matrix, TG2 is thought to function as a suppressor of cellular invasion. We have recently uncovered that the TG2 gene (TGM2) is a target for epigenetic silencing in breast cancer, highlighting a molecular mechanism that drives reduced TG2 expression, and this aberrant molecular event may contribute to invasiveness in this tumor type. Because tumor invasiveness is a primary determinant of brain tumor aggressiveness, we sought to determine if TGM2 is targeted for epigenetic silencing in glioma. Analysis of TGM2 gene methylation in a panel of cultured human glioma cells indicated that the 5' flanking region of the TGM2 gene is hypermethylated and that this feature is associated with reduced TG2 expression as judged by immunoblotting. Further, culturing glioma cells in the presence of the global DNA demethylating agent 5-aza-2'-deoxycytidine and the histone deacetylase inhibitor Trichostatin A resulted in re-expression of TG2 in these lines. In primary brain tumors we observed that the TGM2 promoter is commonly hypermethylated and that this feature is a cancer-associated phenomenon. Using publically available databases, TG2 expression in gliomas was found to vary widely, with many tumors showing overexpression or underexpression of this gene. Since overexpression of TG2 leads to resistance to doxorubicin through the ectopic activation of NFκB, we sought to examine the effects of recombinant TG2 expression in glioma cells treated with commonly used brain tumor therapeutics. We observed that in addition to doxorubicin, TG2 expression drove resistance to CCNU; however, TG2 expression did not alter sensitivity to other drugs tested. Finally, a catalytically null mutant of TG2 was also able to support doxorubicin resistance in glioma cells indicating that transglutaminase activity is not necessary for the resistance phenotype.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20596752      PMCID: PMC3019272          DOI: 10.1007/s11060-010-0277-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  58 in total

1.  Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.

Authors:  Shoichi Nagai; Kazuo Washiyama; Masanori Kurimoto; Akira Takaku; Shunro Endo; Toshiro Kumanishi
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

2.  Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity.

Authors:  S N Prasanna Murthy; Siiri Iismaa; Gillian Begg; Douglas M Freymann; Robert M Graham; Laszlo Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

3.  Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb.

Authors:  Jason E Boehm; Ugra Singh; Carolyn Combs; Marc A Antonyak; Richard A Cerione
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

Review 4.  Lysosomal enzymes, cathepsins in brain tumour invasion.

Authors:  Natasa Levicar; Tadej Strojnik; Janko Kos; Ricardo A Dewey; Geoffrey J Pilkington; Tamara T Lah
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

5.  Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.

Authors:  Kang-Seo Park; Hyun-Kyoung Kim; Jung-Hwa Lee; Yong-Bock Choi; Seong-Yeol Park; Sei-Hoon Yang; Soo-Youl Kim; Kyeong-Man Hong
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-18       Impact factor: 4.553

6.  Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion.

Authors:  Marc A Antonyak; Bo Li; Andrew D Regan; Qiyu Feng; Stephanie S Dusaban; Richard A Cerione
Journal:  J Biol Chem       Date:  2009-04-29       Impact factor: 5.157

Review 7.  Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review).

Authors:  Stephen B Hunter; Daniel J Brat; Jeffrey J Olson; Andreas Von Deimling; Wei Zhou; Erwin G Van Meir
Journal:  Int J Oncol       Date:  2003-10       Impact factor: 5.650

Review 8.  Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion.

Authors:  Anita C Bellail; Stephen B Hunter; Daniel J Brat; Chalet Tan; Erwin G Van Meir
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

9.  Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas.

Authors:  Huamin Wang; Hua Wang; Wei Zhang; Helen J Huang; Warren S L Liao; Gregory N Fuller
Journal:  Lab Invest       Date:  2004-08       Impact factor: 5.662

Review 10.  Tissue transglutaminase promotes or suppresses tumors depending on cell context.

Authors:  Arnav Chhabra; Amit Verma; Kapil Mehta
Journal:  Anticancer Res       Date:  2009-06       Impact factor: 2.480

View more
  19 in total

Review 1.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

Review 2.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

3.  Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization.

Authors:  Soner Gundemir; Gozde Colak; Julianne Feola; Richard Blouin; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2012-10-17

Review 4.  Transglutaminase regulation of cell function.

Authors:  Richard L Eckert; Mari T Kaartinen; Maria Nurminskaya; Alexey M Belkin; Gozde Colak; Gail V W Johnson; Kapil Mehta
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

5.  Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression.

Authors:  Lingbao Ai; Ryan R Skehan; John Saydi; Tong Lin; Kevin D Brown
Journal:  J Biol Chem       Date:  2012-04-04       Impact factor: 5.157

6.  A Bayesian ensemble approach with a disease gene network predicts damaging effects of missense variants of human cancers.

Authors:  Hong-Hee Won; Jong-Won Kim; Doheon Lee
Journal:  Hum Genet       Date:  2012-08-21       Impact factor: 4.132

Review 7.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

8.  CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.

Authors:  B Min; H Park; S Lee; Y Li; J-M Choi; J Y Lee; J Kim; Y D Choi; Y-G Kwon; H-W Lee; S-C Bae; C-O Yun; K C Chung
Journal:  Oncogene       Date:  2015-11-16       Impact factor: 9.867

9.  RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis.

Authors:  Elnaz Atabakhsh; Jean H Wang; Xu Wang; David E Carter; Caroline Schild-Poulter
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

10.  The complex role of transglutaminase 2 in glioblastoma proliferation.

Authors:  Soner Gundemir; Alina Monteagudo; Abdullah Akbar; Jeffrey W Keillor; Gail V W Johnson
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.